178 related articles for article (PubMed ID: 38412388)
21. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome.
Amadou A; Achatz MIW; Hainaut P
Curr Opin Oncol; 2018 Jan; 30(1):23-29. PubMed ID: 29076966
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
24. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
25. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
[TBL] [Abstract][Full Text] [Related]
27. Gastric cancer in individuals with Li-Fraumeni syndrome.
Masciari S; Dewanwala A; Stoffel EM; Lauwers GY; Zheng H; Achatz MI; Riegert-Johnson D; Foretova L; Silva EM; Digianni L; Verselis SJ; Schneider K; Li FP; Fraumeni J; Garber JE; Syngal S
Genet Med; 2011 Jul; 13(7):651-7. PubMed ID: 21552135
[TBL] [Abstract][Full Text] [Related]
28. Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.
Sorrell AD; Espenschied CR; Culver JO; Weitzel JN
Mol Diagn Ther; 2013 Feb; 17(1):31-47. PubMed ID: 23355100
[TBL] [Abstract][Full Text] [Related]
29. Multiple Germline Events Contribute to Cancer Development in Patients with Li-Fraumeni Syndrome.
Subasri V; Light N; Kanwar N; Brzezinski J; Luo P; Hansford JR; Cairney E; Portwine C; Elser C; Finlay JL; Nichols KE; Alon N; Brunga L; Anson J; Kohlmann W; de Andrade KC; Khincha PP; Savage SA; Schiffman JD; Weksberg R; Pugh TJ; Villani A; Shlien A; Goldenberg A; Malkin D
Cancer Res Commun; 2023 May; 3(5):738-754. PubMed ID: 37377903
[TBL] [Abstract][Full Text] [Related]
30. A first report of a rare TP53 variant associated with Li-Fraumeni syndrome manifesting as invasive breast cancer and malignant solitary fibrous tumor.
Prejac J; Dedić Plavetić N; Gotovac Jerčić K; Borovečki F
World J Surg Oncol; 2021 Aug; 19(1):254. PubMed ID: 34452612
[TBL] [Abstract][Full Text] [Related]
31. A Rare
Powers J; Pinto EM; Barnoud T; Leung JC; Martynyuk T; Kossenkov AV; Philips AH; Desai H; Hausler R; Kelly G; Le AN; Li MM; MacFarland SP; Pyle LC; Zelley K; Nathanson KL; Domchek SM; Slavin TP; Weitzel JN; Stopfer JE; Garber JE; Joseph V; Offit K; Dolinsky JS; Gutierrez S; McGoldrick K; Couch FJ; Levin B; Edelman MC; Levy CF; Spunt SL; Kriwacki RW; Zambetti GP; Ribeiro RC; Murphy ME; Maxwell KN
Cancer Res; 2020 Sep; 80(17):3732-3744. PubMed ID: 32675277
[TBL] [Abstract][Full Text] [Related]
32. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
[TBL] [Abstract][Full Text] [Related]
33. Association between Predicted Effects of
Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
[TBL] [Abstract][Full Text] [Related]
34. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
35. Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.
Etzold A; Schröder JC; Bartsch O; Zechner U; Galetzka D
Fam Cancer; 2015 Mar; 14(1):161-5. PubMed ID: 25226867
[TBL] [Abstract][Full Text] [Related]
36. A pedigree-based prediction model identifies carriers of deleterious de novo mutations in families with Li-Fraumeni syndrome.
Gao F; Pan X; Dodd-Eaton EB; Recio CV; Montierth MD; Bojadzieva J; Mai PL; Zelley K; Johnson VE; Braun D; Nichols KE; Garber JE; Savage SA; Strong LC; Wang W
Genome Res; 2020 Aug; 30(8):1170-1180. PubMed ID: 32817165
[TBL] [Abstract][Full Text] [Related]
37. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
[TBL] [Abstract][Full Text] [Related]
38. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
[TBL] [Abstract][Full Text] [Related]
39. From uncertainty to pathogenicity: clinical and functional interrogation of a rare
Quinn EA; Maciaszek JL; Pinto EM; Phillips AH; Berdy D; Khandwala M; Upadhyaya SA; Zambetti GP; Kriwacki RW; Ellison DW; Nichols KE; Kesserwan C
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 30886117
[TBL] [Abstract][Full Text] [Related]
40. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
